Home > Cell Selection & Expansion > Fluorescent Cell Staining > About the Streptamer® Technology > Uncompromised, authentic cells for research and diagnostics

Streptamer® Key Features:

Streptamers®: Full reversibility and preserved function of isolated cells

Reversible Streptamers® confer full protection against L. monocytogenes infection in mice (Knabel et al., 2002)

The reversible Streptamers® maintain the in vivo function of isolated cells. In contrast, conventional MHC multimers/tetramers signifcantly change the phenotype and function of stained T cells at physiological temperatures (Knabel et al., 2002).

Pretreatment of LLO91-99-specific T cells with conventional binding MHC tetramer reagents resulted in significantly reduced protection towards Listeria infection following adoptive transfer. In contrast, after complete removal of the Streptamers® with biotin, the same number of cells conferred almost an identical degree of protection as compared with positive controls.

Without removal of the Streptamers® before adoptive cell transfer, the cells were reproducibly more effective than cells coated with conventional MHC tetramers. Please read the complete paper Knabel et al., 2002.

Reversible Streptamers® preserve proliferation capacity and functional status of CD8+ T cells (Wang et al., 2013)

Proliferation of CMVpp65-specific CD8+ T lymphocytes was preserved after selection with reversible Streptamers®, while it might have been altered with tetramers (Fig.3). Furthermore, the functional status as measured by activity (secretion of IFN-gamma) and cytotoxic effectiveness (secretion of granzyme B) remained very active when selected with Streptamers® as compared to tetramers (Fig.4).

Reversible Streptamers® preserve T cell receptor expression of CD8+ T cells (Zhang et al., 2016)

Streptamers®: Full reversibility and excellent staining intensities

Streptamers® are fully reversible Zhang et al., 2016

Streptamers® can be completely removed from the surface of antigen-specific T cells, and staining intensities are the same like that of conventional tetramers.

Streptamer® is more accurate than Pentamer Ciáurriz et al., 2016

Streptamer® is more accurate than pentamer for the detection of CTLA*02:01-CMVpp65495-503 and can be used not only for the monitoring of early CTLA*02:01-CMVpp65495-503 reconstitution in immunosuppressed patients following allo-HSCT but also, in conjunction with its reversibility role, for the isolation of CTLA*02:01-CMVpp65495-503 for its future use in adoptive immunotherapy.

Streptamers® are superior to tetramers and pentamers

Streptamer® is more accurate than Pentamer Ciáurriz et al., 2016

Streptamer® is more accurate than pentamer for the detection of CTLA*02:01-CMVpp65495-503 and can be used not only for the monitoring of early CTLA*02:01-CMVpp65495-503 reconstitution in immunosuppressed patients following allo-HSCT but also, in conjunction with its reversibility role, for the isolation of CTLA*02:01-CMVpp65495-503 for its future use in adoptive immunotherapy.

Streptamers® showed the best T cell yield as well as the best level and stability of enrichment. Govers et al., 2012

Streptamers®, when compared with tetramers and pentamers, showed the best T cell yield as well as the best level and stability of enrichment of TCR enigneered T cells.

Streptamers® allow predicition of cell reactivity. Hombrink et al., 2013

MHC tetramer staining is not always predicitive for specific T cell reactivity whereas Streptamers® allow a correlation between functional and structural avidity.

Streptamers® preserve cell function Neudorfer et al., 2007

Streptamers® preserve cell function, whereas lytic efficacy and proliferation is impaired in the presence of conventional tetramers.

Streptamer® history

Dirk H. Busch, the inventor of the Streptamer® technology, introduced the Streptamers® in the June 2002 issue of Nature Medicine. He describes the Streptamer® approach as a method to isolate, for the first time, fully functional antigen-specific T cells that are indistinguishable from untreated cells. This is in contrast to the unfavorable effects of conventional multimer techniques. Busch´s experiments in mice demonstrate that the Streptamer® technology is capable to provide antigen-specific T cells, which can be efficiently applied in adoptive transfer protocols.

Later, Schmitt et al. reported that adoptive transfer and selective reconstitution of Streptamer®-selected cytomegalovirus-specific CD8+ T cells lead to virus clearance in patients after allogeneic peripheral blood stem cell transplantation.

Meanwhile, the number of scientific papers describing the advantages of the Streptamers® (see top of the page) in different applications is constantly increasing.

The Streptamer® technology is likely to advance basic cell research as an essential prerequisite for novel immunological medicines.

References: